<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with the <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e> and Diamond-Blackfan <z:hpo ids='HP_0001903'>anemia</z:hpo> (<z:chebi fb="28" ids="35299">DBA</z:chebi>) suffer from a severe <z:hpo ids='HP_0001972'>macrocytic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e> and <z:chebi fb="28" ids="35299">DBA</z:chebi> are disorders of aberrant ribosome biogenesis (ribosomopathies) and haploinsufficiency of the ribosomal protein genes RPS14 and RPS19, respectively, underlies the <z:hpo ids='HP_0001903'>anemia</z:hpo> found in these disorders </plain></SENT>
<SENT sid="2" pm="."><plain>Erythroblasts obtained from patients with the <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e> and <z:chebi fb="28" ids="35299">DBA</z:chebi> show impaired <z:chebi fb="2" ids="33699">mRNA</z:chebi> translation and this defect in translation may represent a potential therapeutic target in these ribosomopathies </plain></SENT>
<SENT sid="3" pm="."><plain>There are some indications that the amino acid l-leucine, a translation enhancer, may have some efficacy in this group of disorders </plain></SENT>
<SENT sid="4" pm="."><plain>Recent studies have shown that l-leucine treatment of zebrafish and murine models of the <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e> and <z:chebi fb="28" ids="35299">DBA</z:chebi> results in a marked improvement in the <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>l-leucine treatment of RPS14-deficient and RPS19-deficient erythroblasts and erythroblasts from patients with the <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e> has been shown to result in an increase in cell proliferation, erythroid differentiation and <z:chebi fb="2" ids="33699">mRNA</z:chebi> translation in culture </plain></SENT>
<SENT sid="6" pm="."><plain>l-leucine has been shown to improve <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> levels and transfusion independence in a patient with <z:chebi fb="28" ids="35299">DBA</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>l-leucine activates the mTOR (mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi>) signaling pathway that controls cell growth and <z:chebi fb="2" ids="33699">mRNA</z:chebi> translation </plain></SENT>
<SENT sid="8" pm="."><plain>There is evidence to suggest that the promotion of translation via the mTOR pathway by l-leucine is the mechanism that underlies the enhanced erythroid progenitor cell growth and differentiation observed in animal and cellular models of the <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e> and <z:chebi fb="28" ids="35299">DBA</z:chebi> treated with this amino acid </plain></SENT>
<SENT sid="9" pm="."><plain>These data support the rationale for clinical trials of l-leucine as a therapeutic agent for the <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e> and <z:chebi fb="28" ids="35299">DBA</z:chebi> </plain></SENT>
</text></document>